

REFERENCES

- Abdallah, M.; Abdel-Naser, M.B.; Moussa, M.H.; Assaf, C. and Orfanos, C.E. (2003):** Sequential immunohistochemical study of depigmenting and repigmenting minigrafts in vitiligo. *Eur. J. Dermatol.*, 13: 548–552.
- Abdel-Naser, M.B.; Krueger, S.; Krasagakis, K.; Garbe, C.; Gollnick, H.; Orfanos, C.E. (1994):** Evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. *Pigment Cell Res.*, 7:1-8.
- Abdul Hameed, A.; Rani, Z. and Kazmi, A.H. (2005):** Vitiligo: New etiology-based treatments. *J. Pak. Ass. Dermatol.*, 15: 252-260.
- Acikel, C.; Ulkur, E. and Celikoz, B. (2007):** 'Application of lasers in transplantation procedures for vitiligo'. In: Gupta S, Olsson MJ, Kanwar AJ and Ortonne JP (eds.). *Surgical Management of Vitiligo*. Singapore: Blackwell Publishing, 259–266.
- Ada, S.; Sahin, S.; Boztepe, G.; Karaduman, A. and Kolemen, F. (2005):** No additional effect of topical calcipotriol on narrow- band UVB phototherapy in patients with generalized vitiligo. *Photodermatol. Photoimmunol. Photomed.*, 21: 79- 83.
- Agarwal, U.S.; Gulati, R.; Shukla, S.R. and Mathur, N. (2004):** Satellite repigmentation after punch grafting. *Int. J. Dermatol.*, 43: 273–274.
- Agrawal, K. and Agrawal, A. (1995):** Vitiligo: repigmentation with dermabrasion and thin split-thickness skin graft. *Dermatol. Surg.*, 21: 295–300.
- Akar, A.; Tunca, M.; Koc, E. and Kurumlu, Z. (2009):** Broadband targeted UVB phototherapy for localized vitiligo: a retrospective study. *Photodermatol. Photoimmunol. Photomed.*, 25: 161–163.
- Akobeng, A.K. (2005):** Understanding systematic reviews and meta-analysis. *Arch. Dis. Child.*, 90: 845–848.
- Akyol, M.; Celik, V.K.; Ozcelik, S.; Polat, M.; Marufihah, M. and Atalay, A. (2002):** The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. *Eur. J. Dermatol.*, 1: 24–26.
- Albert, S.; and Sheno, S.D. (2001):** Acetate sheets in the transfer of epidermal grafts in vitiligo. *J. Am. Acad. Dermatol.*, 44: 719–720.

- Alkhateeb, A.; Fain, P.R.; Thody, A.; Bennett, D.C. and Spritz, R.A. (2003):** Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. *Pigment Cell Res.*, 16(3) :208-214.
- Al-Mutairi, N.; Manchanda, Y.; Al-Doukhi, A. And Al-Haddad, A. (2010):** Long-term results of split-skin grafting in combination with excimer laser for stable vitiligo. *Dermatol. Surg.*, 36(4): 499–505.
- Al-Otaibi, S.R.; Zadeh, V.B.; Al-Abdulrazzaq, A.H.; Tarrab, S.M , Al-Owaidi, H.A. and Mahrous, R. (2009):** Using a 308-nm excimer laser to treat vitiligo in Asians. *Acta. Dermatovenerol. A.P.A.*, 18(1): 13-19.
- Alzolibani, A. (2009):** Genetic epidemiology and heritability of vitiligo in the Qassim region of Saudi Arabia. *Acta. Dermatovenerol. A.P.A.*, 18(3): 119-125.
- Ameen, M.; Exarchou, V.; and Chu, A.C. (2001):** Topical calcipotriol as monotherapy and in combination with psoralen plus ultraviolet A in the treatment of vitiligo. *Br. J. Dermatol.*, 145: 476–479.
- Anbar, T.S.; Westerhof, W.; Abdel Rahman, A.T.; Ewis, A.A. and El Khayyat, M.A. (2008):** Effect of one session of ER:YAG laser ablation plus topical 5-Fluorouracil on the outcome of short-term NB-UVB phototherapy in the treatment of non segmental vitiligo: A left-right comparative study. *Photodermatol. Photoimmunol. Photomed.*, 24: 322-329.
- Arca, E.; Tastan, H.B.; Erbil, A.H.; Sezer, E.; Koc, E. and Kurumlu, Z. (2006):** Narrow-band ultraviolet B as monotherapy and in combination with topical calcipotriol in the treatment of vitiligo. *J. Dermatol.*, 33: 338–343.
- Asawanonda, P.; Charoenlap, M. and Korkij, W. (2006):** Treatment of localized vitiligo with targeted broadband UVB phototherapy: A pilot study. *Photodermatol Photoimmunol. Photomed.*, 22: 133-136.
- Asawanonda, P.; Kijluakiat, J.; Korkij, W. and Sindhupak, W. (2008):** Targeted Broadband Ultraviolet B phototherapy produces similar responses to targeted Narrowband Ultraviolet B phototherapy for vitiligo: a randomized, double-blind study. *Acta. Dermatovenerol.*, 88: 376–381.
- Aslanian, F.M.N.; Noé, R.A.M.; Antelo, D.P.; Farias, R.E.; Das, P.K.; Galadari, D.; et al. (2008):** Immunohistochemical Findings in

- Active Vitiligo Including Depigmenting Lesions and Non-Lesional Skin. *The Open Dermatol. J.*, 2:110-115.
- Babu, A.; Thappa, D.M.; and Jaisankar, T.J. (2008):** Punch grafting versus suction blister epidermal grafting in the treatment of stable lip vitiligo. *Dermatol. Surg.*, 34: 166–178.
- Bakis-Petsoglou, S.; Le Guay, J.L. and Wittal, R. (2009):** A randomized double-blinded, placebo controlled trial of pseudocatalase cream and narrowband ultraviolet B in treatment of vitiligo. *Br. J. Dermatol.*, 161: 910–917.
- Bakos, L.; and Bakos, R.M. (2007):** Focal acne during topical tacrolimus therapy for vitiligo. *Arch. Dermatol.*, 143: 1223–1224.
- Banerjee, K.; Barbhuiya, J.N.; Ghosh, A.P.; Dey, S.K. and Karmakar, P.R. (2003):** The efficacy of low-dose oral corticosteroids in the treatment of vitiligo patient. *Indian J. Dermatol. Venereol. Leprol.*, 69: 135-137.
- Barman, K.D.; Khaitan, B.K. and Verma, K.K. (2004):** A comparative study of punch grafting followed by topical corticosteroid versus punch grafting followed by PUVA therapy in stable vitiligo. *Dermatol. Surg.*, 30: 49–53.
- Barton, S. (2000):** Which clinical studies provide the best evidence: The best RCT still trumps the best observational study. *Br. Med. J.*, 321: 255–259.
- Basak, P.Y.; Adiloglu, A.K.; Ceyhan, A.M.; Tas, T. and Akkaya, V.B. (2008):** The role of helper and regulatory T cells in the pathogenesis of vitiligo. *J. Am. Acad. Dermatol.*, 60 (2): 256-260.
- Bassiouny, D.A. (2010):** Punch Grafting in Vitiligo: Different Factors which Affect the Results. *J. Egypt Women Dermatol. Soc.*, 7: 16-21.
- Beck, A.J.; Phillips, J.; Smith-Thomas, L.; Short, R.D. and MacNeil, S. (2003):** Development of a plasma polymerized surface suitable for the transplantation of keratinocyte-melanocyte cocultures for patients with vitiligo. *Tissue Eng.*, 9: 1123–1131.
- Behl, P.N.; Aggarwal, A. and Srivastava, G. (2003):** 'Vitiligo' In : Behl PN, Srivastava G, (eds.). *Practice of Dermatology*. 9th ed. C.B.S Publishers: New Delhi, 238-241.
- Behl, P.N.; Azad, O.; Kak, R. and Srivastava, G. (1999):** Autologous thin Thierschs Grafts in vitiligo: Experience of 8000 cases 50000

- grafts (1959-98) with modified technique in 198 cases in the year 1997-98. *Indian J. Derm. Venereol. Leprol.*, 65: 117–121.
- Belsey, J. (2009):** What is evidence-based medicine? London: Hayward Medical Communications, 1–10.
- Berneburg, M.; Plettenberg, H. and Krutmann, J. (2000):** Photoaging of human skin. *Photodermatol. Photoimmunol. Photomed.*, 16: 239–244.
- Bhatnagar, A.; Kanwar, A.J.; Parsad, D. and De, D. (2007):** Comparison of systemic PUVA and NBUVB in the treatment of vitiligo: an open prospective study. *J. Eur. Acad. Dermatol. Venereol.*, 21: 638–642.
- Bieber, T.; Cork, M. and Ellis, C. (2005):** Sensus statement on the safety profile of topical calcineurin inhibitors. *Dermatol.*, 211: 77–78.
- Bigby, M. (1998):** Evidence-based medicine in a nutshell. A guide to finding and using the best evidence in caring for patients. *Arch Dermatol.*, 134: 1609-1615.
- Bigby, M. (2000):** Paradigm lost. *Arch. Dermatol.*, 136: 26-31.
- Bigby, M. and Gadenne, A.S. (1996):** Understanding and evaluating clinical trials. *J. Am. Acad. Dermatol.*, 34: 555-559.
- Bigby, M.; Corona, R. and Szklo, M. (2008):** 'Evidence-based dermatology'. In: Wolf K (eds.). *Fitzpatrick's dermatology in general medicine*. 7th ed. New York : McGraw-Hill, 8-18.
- Birlea, S.A.; Costin, G.E. and Norris, D.A. (2008a):** Cellular and molecular mechanisms involved in the action of vitamin D analogs targeting vitiligo depigmentation. *Curr. Drug. Targets*, 9: 345-359.
- Birlea, S.A.; Fain, P.R. and Spritz, R.A. (2008b):** A Romanian population isolate with high frequency of vitiligo and associated autoimmune diseases. *Arch. Dermatol.*, 144(3): 310–316.
- Birol, A.; Kisa, U.; Kurtipek, G.S.; Kara, F.; Kocak, M.; Erkek, E.; et al. (2006):** Increased tumor necrosis factor alpha (TNF- α) and interleukin 1 alpha (IL1- α) levels in the lesional skin of patients with nonsegmental vitiligo. *Int. J. Dermatol.*, 45: 992–993.
- Boissy, R.E. and Manga, P. (2004):** On the etiology of contact/occupational vitiligo. *Pigment Cell Res.*, 17: 208-214.
- Boone, B.; Ongenae, K.; Van Geel, N.; Vernijns, S.; De Keyser, S. and Naeyaert, J.M. (2007):** Topical pimecrolimus in the treatment of vitiligo. *Eur. J. Dermatol.*, 17(1): 55-61.
-

- Borderé, A.C.; Lambert, J. and Van Geel, N. (2009):** Current and emerging therapy for the management of vitiligo. *Clin. Cosm. Investig. Dermatol.*, 2: 15-25.
- Brazzelli, V.; Antoninetti, M.; Palazzini, S.; Barbagallo, T.; De Silvestri, A. and Borroni, G. (2007):** Critical evaluation of the variants influencing the clinical response of vitiligo: study of 60 cases treated with ultraviolet B narrow-band phototherapy. *J. Eur. Acad. Dermatol. Venereol.*, 21(10):1369-1374.
- Bruner, C.R.; Feldman, S.R.; Ventrapragada, M. and Fleischer, A.B. (2003):** A systematic review of adverse effects associated with topical treatment of psoriasis. *Dermatol. Online J.*, 9(1): 2.
- Caelles, I.P.; Pinto, P.H.; Casado, L.D.E.L. and Laguna, R.D.L. (2005):** Focal hypertrichosis during topical tacrolimus therapy for childhood vitiligo. *Pediatr. Dermatol.*, 22: 86–87.
- Callis, K.P. and Krueger, G.G. (2003):** 'Topical agents in the treatment of moderate-to-severe psoriasis'. In: Weinstein GD, Gottlieb AB, (eds.). *Therapy of moderate-to-severe psoriasis*. 2nd ed. New York: Marcel Dekker, 29-51.
- Camacho, F. and Mazuecos, J. (1999):** Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. *Arch. Dermatol.*, 135: 216–217.
- Camacho, F. and Mazuecos, J. (2002):** Oral and topical L-phenylalanine, clobetasol propionate, and UVA / sunlight—a new study for the treatment of vitiligo. *J. Drugs Dermatol.*, 1: 127–131.
- Carg, A.x.; Hackam, D. and Tonelli, M. (2008):** Systematic Review and Meta-analysis: When One Study Is Just not Enough. *Clin. J. Am. So. Nephrol.*, 3: 253–260.
- Cario-Andre', M.; Pain, c.; Gauthier, Y. and Taieb, A. (2007):** The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis. *Pigment Cell Res.*, 20: 385–393.
- Carlie, G.; Ntusi, N.B.A.; Hulley P.A. and Kidson, S.H. (2003):** KUVA (khellin plus ultraviolet A) stimulates proliferation and melanogenesis in normal human melanocytes and melanoma cells in vitro. *Br. J. Dermatol.*, 149(4): 707 - 717
- Casacci, M.; Thomas, P.; Pacifico, A.; Bonnevalle, A.; Paro Vidolin, A. and Leone, G. (2007):** Comparison between 308-nm monochromatic excimer light and narrowband UVB phototherapy

- (311–313 nm) in the treatment of vitiligo—a multicentre controlled study. *J. Eur. Acad. Dermatol. Venereol.*, 21: 956–963.
- Chen, G.Y.; Hsu, M.M.; Tai, H.K.; Chou, T.C.; Tseng, C.L.; Chang, H.Y.; et al. (2005):** Narrow-band UVB treatment of vitiligo in Chinese. *J. Dermatol.*, 32(10): 793-800.
- Chen, Y.F.; Yang, P.Y.; Hu, D.N.; Kuo, F.S.; Hung, C.S.; and Hung, C.M. (2004):** Treatment of vitiligo by transplantation of cultured pure melanocyte suspension: analysis of 120 cases. *J. Am. Acad. Dermatol.*, 51: 68–74.
- Cherif, F.; Azaiz, M.I.; Ben Hamida, A.; Ben, O. and Dhari, A. (2003):** Calcipotriol and PUVA as treatment for vitiligo. *Dermatol Online J*, 9: 4.
- Chiaverini, C.; Passeron, T. and Ortonne, J.P. (2002):** Treatment of vitiligo by topical calcipotriol. *J. Eur. Acad. Dermatol.*, 16: 137-138.
- Choi, C.W.; Chang, S.E.; Bak, H.; Choi, J.H.; Park, H.S.; Huh, C.H.; et al. (2008) :** Topical immunomodulators are effective for treatment of vitiligo. *J. Dermatol.*, 35(8): 503–507.
- Chopra, A.; Singh, S.P.; Mittal, R.R. and Puri, R. (1996):** Oral psoralens vs injection placental extract plus oral psoralens in vitiligo. *Indian J. Dermatol. Venereol. Leprol.*, 62: 22-23.
- Cohen, A.M.; Stavri, P.Z. and Hersh, W.R. (2004):** A categorization and analysis of the criticisms of evidence-based medicine. *Int. J. Med. Inf.*, 73(1): 35-43.
- Concato, J.; Shah, N. and Horwitz, R. (2000):** Randomized, controlled trials, observational studies, and the hierarchy of research design. *N. Engl. J. Med.*, 342: 1887-1890.
- Coskun, B.; Saral, Y. and Turgut, D. (2005):** Topical 0.05% clobetasol propionate versus 1% pimecrolimus ointment in vitiligo. *Eur. J. Dermatol.*, 15(2): 88-91.
- Craig, J.C.; Irwig, L.M. and Stockler, M.R. (2001):** Evidence-based medicine: useful tools for decision making. *Med. J. Aust.*, 174: 248-53.
- Crombie, I.K. and Davies, H.T.O. (2009):** What is meta-analysis? Accessed 28 october 2009, <<http://www.whatisseries.co.uk>>
- Cucchi, M.L.; Frattini, P.; Santagostino, G. and Orecchia, G. (2000):** Higher plasma catecholamine and metabolite levels in the early phase of nonsegmental vitiligo. *Pigment Cell Res.*, 13: 28-32.

- Cui, J.; Arita, Y. and Bystryń, J.C. (1995):** Characterization of vitiligo antigens, *Pigment Cell Res.*, 8:53-59.
- Czajkowski, R.; Placek, W.; Drewa, T.; Kowaliszyn, B.; Sir, J. and Weiss, W. (2007):** Autologous cultured melanocytes in vitiligo treatment. *Dermatol. Surg.*, 33: 1027–1036.
- Dawid, M.; Veensalu, M.; Grassberger, M.; and Wolff, K. (2006):** Efficacy and safety of pimecrolimus cream 1% in adult patients with vitiligo: results of a randomized.; double-blind.; vehicle-controlled study. *J. Dtsch. Dermatol. Ges.*, 4: 942–946.
- De Haes, P.; Garmyn, M.; Verstuyf, A.; De Clercq, P.; Vandewalle, M.; Degreef, H.; et al (2005):** 1,25-dihydroxyvitamin D3 and analogues protect primary human keratinocytes against UVB-induced DNA damage. *J. Photochem. Photobiol.*, 78: 141–148.
- De Leeuw, J.; van der Beek, N.; Maierhofer, G. and Neugebauer, W.D. (2003):** A case study to evaluate the treatment of vitiligo with khellin encapsulated in L-phenylalanin stabilized phosphatidylcholine liposomes in combination with ultraviolet light therapy. *Eur. J. Dermatol.*, 13(5): 474-477.
- Del Rosso, J. and Friedlander, S.F. (2005):** Corticosteroids: options in the era of steroid-sparing therapy. *J. Am. Acad. Dermatol.*, 53 (Suppl. 1): S50-S58.
- Dell'Anna, M.L. and Picardo, M. (2006):** A review and a new hypothesis for non immunological pathogenetic mechanisms in vitiligo. *Pigment Cell Res.*, 19: 406-411.
- Dell'Anna ML, Mastrofrancesco A, Sala R, Venturini M.; Ottaviani, M.; Viodolin, A.P.; et al. (2007):** Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. *Clin. Exp. Dermatol.*, 32: 631-636.
- Denman, C.J.; McCracken, J.; Hariharan, V.; Klarquist, J.; Oyarbide-Valencia, K.; Guevara-Patiño, J.A.; et al. (2008):** HSP7 accelerates depigmentation in a mouse model of autoimmune vitiligo. *J. Investig. Dermatol.*, 128(8): 2041-2048.
- Dolua, N.; Ferahbaş, A.; Özermiş, C.; Peker D and Açık, C. (2004):** Effect of PUVA therapy on electrodermal activity parameters in vitiligo patients. *Auton. Neurosci.*, 118: 102-107.

- Don, P.; Iuga, A.; Dacko, A. and Hardick, K. (2006):** Treatment of vitiligo with broadband ultraviolet B and vitamins. *Int. J. Dermatol.*, 45: 63–65.
- Eddy, D.M. (2005):** Evidence-based medicine: a unified approach. *Health Aff.*, 24 (1): 9–17.
- El Dib, R.P.; Atallah, A.N. and Andriolo, R.B. (2007):** Mapping the Cochrane evidence for decision making in health care. *J. Eval. Clin. Pract.*, 13 (4): 689–692.
- El Mofty, M.; Mostafa, W.; Esmat, S.; Youssef, R.; Azzam, O.; Hunter, N.; et al . (2006):** Narrow band Ultraviolet B 311nm in the treatment of vitiligo: Two right-left comparison studies. *Photodermatol. Photoimmunol. Photomed.*, 22: 6-11.
- Elgoweini, M. and Nour El Din, N. (2009):** Response of vitiligo to narrowband ultraviolet B and oral antioxidants. *J. Clin. Pharmacol.*, 49: 852–855.
- Elstein, A.S. (2004):** On the origins and development of evidence-based medicine and medical decision making. *Inflamm. Res.*, 53 (Suppl. 2): S184–S189.
- Ely, M.C.; Carlos, M.G.A. and Lucia, P.F.D. (2002):** Quantitative study of Langerhans' cells in vitiligo. *Anais brasileiros de dermatol.*, 77(4): 435-445.
- Ermis, O.; Alpsoy, E.; Cetin, L. and Yilmaz, E. (2001):** Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. *Br. J. Dermatol.*, 145: 472-475.
- Esfandiarpour, I.; Ekhlasi, A.; Farajzadeh, S. and Shamsadini, S. (2009):** The efficacy of pimecrolimus 1% cream plus narrow-band ultraviolet B in the treatment of vitiligo: a double-blind, placebo-controlled clinical trial. *J. Dermatolog. Treat.*, 20(1): 14-18.
- Eskandani, M.; Golchai, J.; Pirooznia, N. and Hasannia, S. (2010):** Oxidative stress level and tyrosinase activity in vitiligo patients. *Indian J. Dermatol.*, 55: 15-19.
- Evans, D. (2003):** Hierarchy of evidence: A framework for ranking evidence evaluating healthcare interventions. *J. Clin. Nurs.*, 12: 77–84.
- Eves, P.C.; Bullett, N.A.; Haddow, D.; Beck, A.J.; Layton, C.; Way, L.; et al. (2008):** Simplifying the delivery of melanocytes and

keratinocytes for the treatment of vitiligo using a chemically defined carrier dressing. *J. Invest. Dermatol.*, 128: 1554–1564.

Evidence-Based Medicine Working Group. (1992): Evidence-based medicine. A new approach to teaching the practice of medicine. *J. Am. Med. Ass.*, 268: 2420–2425.

Fai, D.; Cassano, N, and Vena, G.A. (2007): Narrow-band UVB phototherapy combined with tacrolimus ointment in vitiligo: a review of 110 patients. *J. Eur. Acad. Dermatol. Venereol.*, 21: 916-920.

Fain, P.R, Babu, S.R.; Bennett, D.C. and Spritz, R.A. (2006): HLA class II haplotype DRB1*04–DQB1*0301 contributes to risk of familial generalized vitiligo and early disease onset. *Pigment Cell Res.*, 19(1): 51–57.

Falabella, R. (2000): 'Surgical therapies for vitiligo'. In: Hann SK, Nordlund JJ, (eds.). *Vitiligo*. Luc, on, France: Blackwell Science Ltd, 193–200.

Falabella, R. (2005): Surgical approaches for stable vitiligo. *Dermatol. Surg.*, 31(10): 1277–1284.

Falabella, R. and Barona, M.I. (2008): Update on skin repigmentation therapies in vitiligo. *Pigment Cell Melanoma Res.*, 22: 42–65.

Farajzadeh, S.; Daraei, Z.; Esfandiarpour, I. and Hosseini, S.H. (2009): The Efficacy of Pimecrolimus 1% Cream Combined with Microdermabrasion in the Treatment of Nonsegmental Childhood Vitiligo: A Randomized Placebo–Controlled Study. *Pediatr. Dermatol.*, 26(3): 286–291.

Fargnoli, M.C. and Bolognia, J.L.(1995): Pentachrome vitiligo. *J. Am. Acad. Dermatol.*, 33: 853-856.

Farrokhi, S.; Hojjat-Farsangi, M.; Noohpisheh, R, Tahmasbi, R. and Rezaei, N. (2005): Assessment of immune system in Vitiligo. *Eur. Acad. Dermatol. Venereol.*, 19: 706–711.

Fattahi, M.J. and Pezeshki, A.M. (2005): Lack of Association between CTLA-4 A49G Polymorphism and Vitiligo. *Iran. J. Immunol.*, 2(2): 97-102.

Fenton, J. S. and Bergstrom, K.G. (2008): Vitiligo: nonsurgical treatment options and the evidence behind their use. *J. Drugs. Dermatol.*, 7: 705-711.

- Ference, J.D and Last, A.R. (2009):** Choosing Topical Corticosteroids. *Am. Fam. Physician*, 79(2):135-140.
- Forschner, T.; Buchholtz, S. and Stockfleth, E. (2007):** Current state of vitiligo therapy—evidence-based analysis of the literature. *J. Dtsch. Dermatol. Ges.*, 5: 467–475.
- Friedlander, S.F.; Hebert, A.A. and Allen, D.B. (2002):** Safety of fluticasone propionate cream 0.05 % for the treatment of severe and extensive atopic dermatitis in children as young as 3 months. *J. Am. Acad. Dermatol.*, 46(3): 387-393.
- Friedman, L.S. and Richter, E.D. (2004):** Relationship between conflicts of interest and research results. *J. Gen. Intern. Med.*, 19 (1): 51–56.
- Gauthier, Y. (1995a):** Techniques of melanocyte graft. *Ann. Dermatol. Venereol.*, 122: 627–631.
- Gauthier, Y. (1995b):** The importance of Koebner's phenomenon in the induction of vitiligo vulgaris lesions. *Eur. J. Dermatol.*, 5: 704–708.
- Gauthier, Y. and Surleve-Bazeille, J.E. (1992):** Autologous grafting with noncultured melanocytes: a simplified method for treatment of depigmented lesions. *J. Am. Acad. Dermatol.*, 26: 191– 194.
- Gauthier, Y.; Cario-Andre, M. and Taieb, A. (2004):** A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? *Pigment Cell Res.*, 16: 322-332.
- Gauthier, Y.; Carlo Andre, M. and Taïeb, A. (2003):** A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy? *Pigment Cell Res.*, 16(4) :322-332.
- Gawkrodger, D.J.; Ormerod, A.D.; Shaw, L.; Mauri-Sole, I.; Whitton, M.E.; Watts, M.J.; et al. (2008):** Guideline for the diagnosis and management of vitiligo. *Br. J. Dermatol.*, 159(5): 1051-1076.
- Ghorpade, A. (2004).** Use of tissue glue for punch grafting in vitiligo— a preliminary report. *Indian J. Dermatol. Venereol. Leprol.*, 70: 159–161.
- Ghosh, D.; Shenoy, S. and Kuchroo, P. (2008):** Cultured melanocytes: from skin biopsy to transplantation. *Cell Transplant.*, 17: 351–360.
- Ghosh, S. (2010):** Chemical leukoderma: What's new on etiopathological and clinical aspects? *Indian J. Dermatol.*, 55: 255-258.
- Gilhar, A.; Zelickson, B.; Ulman, Y. and Etzioni, A. (1995):** In vivo destruction of melanocytes by the IgG fraction of serum from patients with vitiligo. *J. Invest. Dermatol.*, 105: 683- 686.

- Gloor, M. and Scherotzke, A. (2002):** Age dependence of ultraviolet light-induced erythema following narrow-band UVB exposure. *Photodermatol. Photoimmunol. Photomed.*, 18 (3): 121–126.
- Goktas, E.O.; Aydin, F.; Senturk, N.; Canturk, M.T. and Turanli, A.Y. (2006):** Combination of narrow band UVB and topical calcipotriol for the treatment of vitiligo. *J. Eur. Acad. Dermatol. Venereol.*, 20: 553–557.
- Goldinger, S.M.; Dummer, R.; Schmid, P.; Burg, G.; Seifert, B. and Lächli, S. (2007):** Combination of 308-nm xenon chloride excimer laser and topical calcipotriol in vitiligo. *J. Eur. Acad. Dermatol. Venereol.*, 21(4): 504–508.
- Gopal, K.; Rama Rao, G.R.; Kumar, Y.H.; Appa Rao, M.V.; Vasudev, P.S. (2007):** Vitiligo: A part of a systemic autoimmune process. *Indian J. Dermatol. Venereol. Leprol.*, 73: 162-165.
- Greenhalgh, T. (1997):** How to Read a Paper: The Basics of Evidence Based Medicine. London, Br Med J Publishing Group, accessed 2 April 2007, <<http://www.health.library.mcgill.ca/ebm/greenhalgh.htm>>.
- Greve, B.; Raulin, C. and Fischer, E. (2006):** Excimer laser treatment of vitiligo – critical retrospective assessment of own results and literature overview. *J. Dtsch. Dermatol. Ges.*, 4: 32–40.
- Grimes, P.E. (1997):** Psoralen photochemotherapy for vitiligo. *Clin. Dermatol.*, 15(6): 921-926.
- Grimes, P.E. (2005):** New insights and new therapies in vitiligo. *J. Am Med. Ass.*, 293(6) :730-735.
- Grimes, P.E.; Morris, S.; Avaniss-Aghajani, E.; Soriano, T.; et al. (2004) :** Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. *J. Am. Acad. Dermatol.*, 51(1): 52– 61.
- Grimes, P.E.; Sevall, J.S. and Vojdani, A. (1996):** Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo. *J. Am. Acad. Dermatol.*, 35: 21-26.
- Groysman, V. and Sami, N. (2008):** Vitiligo Emedicine Specialist Dermatology, accessed 30 November 2007, <<http://www.emedicine>>.
- Guerra, L.; Capurro, S.; Melchi, F.; Primavera, G.; Bondanza, S.; Cancedda, R.; et al. (2000):** Treatment of “stable” vitiligo by Timsurgery and transplantation of cultured epidermal autografts. *Arch. Dermatol.*, 136: 1380–1389.

- Guerra, L.; Primavera, G.; Raskovic, D.; Pellegrini, G.; Golisano, O.; Bondanza, S.; et al. (2003):** Erbium: YAG laser and cultured epidermis in the surgical therapy of stable vitiligo. *Arch. Dermatol.*, 139: 1303–1310.
- Gupta, R.P. and Anderson, T.F. (2003):** Psoralen photochemotherapy. *J. Am. Acad. Dermatol.*, 17: 703-704.
- Gupta, S. and Kumar, B. (2002):** Epidermal grafting for vitiligo in adolescents. *Pediatr. Dermatol.*, 19: 159–62.
- Gupta, S. and Kumar, B. (2003):** Epidermal grafting in vitiligo: influence of age, site of lesion, and type of disease on outcome. *J. Am. Acad. Dermatol.*, 104: 99–104.
- Gupta, S. and Shroff, S. (1999):** Modified technique of suction blistering for epidermal grafting in vitiligo. *Int. J. Dermatol.*, 38: 306–309.
- Gupta, S.; Goel, A.; Kanwar, A.J. and Kumar, B. (2006):** Autologous melanocyte transfer via epidermal grafts for lip vitiligo. *Int. J. Dermatol.*, 45: 747–750.
- Gupta, S.; Narang, T.; Olsson, M.J. and Ortonne, J.P. (2007):** 'Surgical management of vitiligo and other leucodermas: evidence-based practice guidelines'. In: Gupta S, Olsson MJ, Kanwar AJ, Ortonne JP, (eds.). *Surgical Management of Vitiligo*. Oxford, UK: Blackwell Publishing Ltd, 69–79.
- Gupta, S.; Sandhu, K.; Kanwar, A. and Kumar, B. (2004):** Melanocyte transfer via epidermal grafts for vitiligo of labial mucosa. *Dermatol. Surg.*, 30: 45–48.
- Gupta, S.; Shroff, S. and Gupta, S. (1999):** Modified technique of suction blistering for epidermal grafting in vitiligo. *Int. J. Dermatol.*, 38: 306–309.
- Guyatt, G.H.; Sackett, D.L. and Cook, D.J. (1994):** Users' guides to the medical literature. II. How to use an article about therapy or prevention. B. What were the results and will they help me in caring for my patients? *J. Am. Med. Ass.*, 271: 59-63.
- Habib, A.; Sheikh, Z.I.; Khan, O.U.D. and Rahman, S.B. (2006):** Efficacy and safety of oral dexamethasone pulse treatment for vitiligo. *Pak. Armed Forces Med. J.*, 56(2):111-115.
- Halder, R. and Taliaferro, S. (2008):** 'Vitiligo'. In: Wolff K, Goldsmith L, Katz S, Gilchrest B, Paller A, Lefell D, (eds.). *Fitzpatrick's*

- Dermatology in General Medicine*. Vol 1. 7th ed. New York, NY: McGraw-Hill, 616-630.
- Halder, R.M. and Young, C.M. (2000):** New and emerging therapies for vitiligo. *Dermatol. Clin.*, 18(1):79-89.
- Halder, R.M.; Grimes, P.E.; Cowan, C.A.; Enterline, J.A.; Chakrabarti, S.G. and Kenney, J.A. (1987):** Childhood vitiligo. *J. Am. Acad. Dermatol.*, 16:948-954.
- Hamzavi, I. and Lui, H. (2005):** Using light in dermatology: An update on lasers, ultraviolet phototherapy, and photodynamic therapy. *Dermatol. Clin.*, 23: 199-207.
- Handa, S. and Dogra, S. (2003):** Epidemiology of childhood vitiligo: A study of 625 patients from North India. *Pediatr. Dermatol.*, 20: 207-10.
- Handa, S.; Pandhi, R. and Kaur, I. (2001):** Vitiligo: a retrospective comparative analysis of treatment modalities in 500 patients. *J. Dermatol.*, 28: 461–466.
- Hann, S.K. (2004):** Clinical variants of vitiligo. *Arch. Dermatol.*, 5: 159-163.
- Hann, S.K.; Chun, W.H. and Park, Y.K. (1997):** Clinical characteristics of progressive vitiligo. *Int J Dermatol*, 36: 353-355.
- Hann, S.K.; Kim, Y.S.; Yoo, J.H. and Chun, Y.S. (2000):** Clinical and histopathologic characteristics of trichrome vitiligo. *J. Am. Acad. Dermatol.*, 42(4): 589-596.
- Hara, M.; Toyoda, M. and Yaar, M. (1996):** Innervation of melanocytes in human skin. *J. Exp. Med.*, 184: 1385-1395.
- Hartmann, A.; Bröcker, E.B. and Hamm, H. (2008):** Occlusive treatment enhances efficacy of tacrolimus 0.1% ointment in adult patients with vitiligo: results of a placebo-controlled 12-months prospective study. *Acta. Dermatovenerol.*, 88(5): 474–479.
- Hartmann, A.; Lurz, C.; Hamm, H.; Brocker, E.B. and Hofmann, U.B. (2005):** Narrow-band UVB 311 nm vs. broad-band UVB therapy in combination with topical calcipotriol vs. placebo in vitiligo. *Int. J. Dermatol.*, 44: 736–742.
- Hasegawa, T.; Suga, Y.; Ikejima, A.; Muramatsu, S.; Mizuno, Y.; Tsuchihashi, H.; et al. (2007):** Suction blister grafting with CO(2) laser resurfacing of the graft recipient site for vitiligo. *J. Dermatol.*, 34: 490–492.

- Hatchome, N.; Kato, T.; and Tagami, H. (1990):** Therapeutic success of epidermal grafting in generalized vitiligo is limited by the Koebner phenomenon. *J. Am. Acad. Dermatol.*, 22: 87–91.
- Haynes, R.B. (2002):** What kind of evidence is it that evidence-Based Medicine advocates want health care providers and consumers to pay attention to? *B.M.C. Health Serv. Res.*, 2(1): 3-9.
- Haynes, R.B. (2006):** Of studies, syntheses, synopses, summaries, and systems: the “5S” evolution of information services for evidence-based healthcare decisions. *Evid. Based Med.*, 11:162-164
- Hearing, V.J. (1999):** Biochemical control of melanogenesis and melanosomal organization. *J. Investig. Dermatol. Symp. Proc.*, 4 (1): 24-28.
- Ho, P.M.; Peterson, P.N. and Masoudi, F.A. (2008):** Evaluating the evidence is there a rigid hierarchy? *Circulation*, 118: 1675-1684.
- Hofer, A.; Hassan, A.S.; Legat, F.J.; Kerl, H. and Wolf, P. (2006):** The efficacy of excimer laser (308 nm) for vitiligo at different body sites. *J. Eur. Acad. Dermatol. Venereol.*, 20: 558–564.
- Hofer, A.; Kerl, H. and Wolf, P. (2001):** Long-term results in the treatment of vitiligo with oral khellin plus UVA. *Eur. J. Dermatol.*, 11: 225–229.
- Hong, S.B.; Park, H.H. and Lee, M.H. (2005):** Short-term Effects of 308-nm Xenon-chloride Excimer Laser and Narrow-band Ultraviolet B in the Treatment of Vitiligo: A Comparative Study. *J. Korean Med. Sci.*, 20: 273-278.
- Hong, W.; Hu, D.; Qian, G.; McCormick, S. and Xu, A. (2010):** Treatment of vitiligo in children and adolescents by autologous cultured pure melanocytes transplantation with comparison of efficacy to results in adults. *J. Eur. Acad. Dermatol. Venereol.*, 24: 830-836.
- Honig, B.; Masreson W.L. and Karp, D. (2002):** photochemotherapy beyond psoriasis. *J. Am. Acad. Dermatol.*, 25: 731-745.
- Horikawa, T.; Mishima, Y.; Nishino, K. and Ichihashi, M. (1999):** Horizontal and vertical pigment spread into surrounding piebald epidermis and hair follicles after suction blister epidermal grafting. *Pigment Cell Res.*, 12: 175–180.
- Huang, X.; Lin, J. and Demner-Fushman, D. (2006):** 'Evaluation of PICO as a knowledge representation for clinical questions'. *A.M.I.A. Ann. Symp. Proc.*, 359–63.

- Iacovelli, P.; Sinagra, J.L.; Vidolin, A.P.; Marenda, S.; Capitanio, B.; Leone, G.; et al. (2005):** Relevance of thyroiditis and of other autoimmune diseases in children with vitiligo. *Dermatol.*, 210: 26-30.
- Ibbotson, S.H.; Bilsland, D. and Cox, N.H. (2004):** An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop report. *Br. J. Dermatol.*, 151: 283–297.
- Ioannidis, J.P. (2005):** Contradicted and initially stronger effects in highly cited clinical research. *J. Am. Med. Ass.*, 294: 218–28.
- Ivker, R.; Goldaber, M. and Buchness, M.R. (1994):** Blue vitiligo. *J. Am. Acad. Dermatol.*, 30: 829-831.
- Jalel, A.; Yassine, M. and Hamdaoui, M.H. (2009):** Oxidative stress in experimental vitiligo C57Bl/6 mice. *Indian J. Dermatol.*, 54: 221-224.
- Jin, Y.; Birlea, S.A.; Fain, P.R. and Spritz, R.A. (2007a):** Genetic variations in NALP1 are associated with generalized vitiligo in a Romanian population. *J. Invest. Dermatol.*, 127: 2558-2562.
- Jin, Y.; Birlea, S.A.; Fain, P.R.; Gowan, K.; Sheri L.; Riccardi, S.L.; et al. (2010):** Variant of TYR and Autoimmunity Susceptibility Loci in Generalized Vitiligo. *N. Engl. J. Med.*, 362 (18): 1686-1697.
- Jin, Y.; Mailloux, C.M.; Gowan, K.; Riccardi, S.L.; La Berge, G.; Bennett, D.C.; et al. (2007b):** NALP1 in vitiligo-associated multiple autoimmune disease. *N. Eng. J. Med.*, 356: 1216-1225.
- Jo, S.J.; Yoon, H.S.; Woo, S.M. and Youn, J.I. (2006):** Time course of tanning induced by narrow-band UVB phototherapy in Korean psoriasis patients. *Photodermatol. Photoimmunol. Photomed.*, 22: 193–199.
- Juni, P.; Altman, D.G. and Egger, M. (2001):** Systematic reviews in health care: Assessing the quality of controlled clinical trials. *Br. Med. J.*, 323: 42–46.
- Kahn, A.M. and Cohen, M.J. (1998):** Repigmentation in vitiligo patients. Melanocyte transfer via ultra-thin grafts. *Dermatol. Surg.*, 24: 365–367.
- Kahn, A.M.; and Cohen, M.J. (1995):** Vitiligo: treatment by dermabrasion and epithelial sheet grafting. *J. Am. Acad. Dermatol.*, 33: 646–648.
- Kane, D.; Barnes, L. and Fitzgerald, O. (1993):** Topical corticosteroid treatment: systemic side-effects. *Br. J. Dermatol.*, 149(2) : 417.

- Kang, H.Y. and Choi, Y.M. (2006):** FK506 increases pigmentation and migration of human melanocytes. *Br. J. Dermatol.*, 155: 1037–1040.
- Kanwar, A.J.; Dogra, S. and Parsad, D. (2004):** Topical tacrolimus for treatment of vitiligo in Asians. *Clin. Exp. Dermatol.*, 29(6): 589–592.
- Kanwar, A.J.; Dogra, S.; Parsad, D. and Kumar, B. (2005):** Narrow-band UVB for the treatment of vitiligo: an emerging effective and well-tolerated therapy. *Int. J. Dermatol.*, 44: 57–60.
- Kavuossi, H. (2009):** Induction of depigmentation in a universal vitiligo patient with combination of cryotherapy and phenol. *J. Pak. Ass. Dermatol.*, 19(2): 112-114.
- Kawalek, A.Z.; Spencer, J.M. and Phelps, R.G. (2004):** Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. *Dermatol. Surg.*, 30: 130–135.
- Kemp, E.H.; Gawkrödger, D.J.; MacNeil, S.; Watson, P.F. and Weetman, A.P. (1997):** Detection of tyrosinase autoantibodies in patients with vitiligo using 35S-labeled recombinant human tyrosinase in a radioimmunoassay. *J. Invest. Dermatol.*, 109: 69-73.
- Kemp, E.H.; Waterman, E.A. and Weetman, A.P. (2001):** Immunological pathomechanisms in vitiligo. *Expert. Rev. Mol. Med.*, 3(20): 1-22.
- Khalid, M.; Mujtaba, G. and Haroon, T.S. (1995):** Comparison of 0.05% clobetasol propionate cream and topical PUVASOL in childhood vitiligo. *Int. J. Dermatol.*, 34: 203–205.
- Khandpur, S.; Sharma, V.K. and Manchandra, Y. (2005):** Comparison of minipunch grafting versus split skin grafting in chronic stable vitiligo. *Dermatol. Surg.*, 31: 436–441.
- Khunger N. (2007):** 'Recent advances in the surgical treatment of vitiligo'. In: Ghosh S, (ed). *Recent advances in dermatology*. India: Jaypee Medical Publishers (P) Ltd., 2: 319–340.
- Khunger, N.; Kathuria, S.D. and Ramesh, V. (2009):** Tissue grafts in vitiligo surgery - past, present, and future. *Indian J. Dermatol.*, 54 (2): 150–158.
- Kiec-Swierczynska, M.; Dudek, B.; Krecisz, B.; Swierczynska-Machura, D.; Dudek, W.; et al. (2006):** The role of psychological factors and psychiatric disorders in skin diseases. *Med. Pr.*, 57(6): 551-555.

- Kim, H.U. and Yun, S.K. (2000):** Suction device for epidermal grafting in vitiligo: employing a syringe and a manometer to provide an adequate negative pressure. *Dermatol. Surg.*, 26: 702–704.
- Kim, J.Y.; Han, B.G.; Park, H.J. and Kim, Y.C. (2006):** Induction of repigmentation in vitiligo after burn injury caused by oral psoralen and ultraviolet A therapy. *Eur. J. Dermatol.*, 16(4): 452-453.
- Kim, Y.J.; Chung, B.S. and Choi, K.C. (2001):** Depigmentation therapy with Q-switched ruby laser after tanning in vitiligo universalis. *Dermatol. Surg.*, 27(11): 969-970.
- Koca, R.; Armutcu, F.; Altinyazar, H.C. and Gurel, A. (2004):** Oxidant-antioxidant enzymes and lipid peroxidation in generalized vitiligo. *Clin. Exp. Dermatol.*, 29: 406-409.
- Koga M. and Tango, T. (1988):** Clinical features and course of type A and type B vitiligo. *Br. J. Dermatol.*, 118: 223-228.
- Kopera, D (2000):** 'History and cultural aspects of vitiligo'. In: Hann SK, Nordlund JJ, (eds.). *Vitiligo*. Oxford: Blackwell Science Ltd., 13-17.
- Kostovic, K.; Pastar, Z.; Pasic, A. and Ceovic, R. (2007):** Treatment of vitiligo with narrow-band UVB and topical gel containing catalase and superoxide dismutase. *Acta. Dermatovenerol. Croat.*, 15: 10-14.
- Kovacs, S.O. (1998):** Vitiligo. *J. Am. Acad. Dermatol.*, 38(5): 647-666.
- Kumaran, M.S.; Kaur, I. and Kumar, B. (2006):** Effect of topical calcipotriol, betamethasone dipropionate and their combination in the treatment of localized vitiligo. *J. Eur. Acad. Dermatol. Venereol.*, 20(3): 269-273.
- Kunisada, M.; Kumimoto, H.; Ishizaki, K.; Sakumi, K.; Nakabeppu, Y. and Nishigori, C. (2007):** Narrow-band UVB induces more carcinogenic skin tumors than broad-band UVB through the formation of cyclobutane pyrimidine dimer. *J. Invest. Dermatol.*, 127: 2865–2871.
- Kunz, R. and Oxman, A. (1999):** Two systematic reviews—two different answers? accessed 28 August 1999, <<http://www.bmj.com/cgi/eletters/319/7205/312>>.
- Kwinter, J.; Pelletier, J.; Khambalia, A. and Pope, E. (2007):** High-potency steroid use in children with vitiligo: a retrospective study. *J. Am. Acad. Dermatol.*, 56(2):236-241.

- Kwok, Y.K.; Anstey, A.V. and Hawk, J.L. (2002):** Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. *Clin. Exp. Dermatol.*, 27: 104–110.
- Laberge, G.; Mailloux, C. M.; Gowan, K.; Holland, P.; Bennett, D.C.; Fain, P.R, et al. (2005):** Early disease onset and increased risk of other autoimmune diseases in familial generalized vitiligo. *Pigment Cell Res.*,18: 300–305.
- Lahiri, K. (2009):** Evolution and evaluation of autologous mini punch grafting in vitiligo. *Indian J. Dermatol.*, 54(2): 159-167.
- Lahiri, K.; Malakar, S.; Sarma, N.; and Banerjee, U. (2006):** Repigmentation of vitiligo with punch grafting and narrow-band UVB(311 nm)–a prospective study. *Int. J. Dermatol.*, 45: 649–655.
- Lan, C.C.; Chen, G.S.; Chiou, M.H.; Wu, C.S.; et al. (2005):** FK506 promotes melanocyte and melanoblast growth and creates a favourable milieu for cell migration via keratinocytes: possible mechanisms of how tacrolimus ointment induces repigmentation in patients with vitiligo. *Br. J. Dermatol.*, 153:498–505.
- Lan, C.C.; Wu, C.S.; Chiou, M.H.; Hsieh, P.C. and Yu, H.S. (2006):** Low-energy helium-neon laser induces locomotion of the immature melanoblasts and promotes melanogenesis of the more differentiated melanoblasts: recapitulation of vitiligo repigmentation in vitro. *J. Invest. Dermatol.*, 126: 2119–2126.
- Lau, J.; Ionnidis, J.P.A. and Schmid, C.H. (1998):** Summing up evidence: One answer is not always enough. *Lancet*, 351: 123-126.
- Laxmisha, C. and Thappa, D.M. (2005a):** Reliable site for suction blister induction and harvesting. *Indian J. Dermatol.Venereol. Leprol.*, 71: 321–324.
- Laxmisha, C. and Thappa, D.M. (2005b):** Surgical pearl: surgical tape for dressing of epidermal grafts in lip vitiligo. *J. Am. Acad. Dermatol.*, 53: 498–499.
- Laxmisha, C. and Thappa, D.M. (2006):** Surgical pearl: use of hypodermic needle to transfer minigrafts. *J. Am. Acad. Dermatol.*, 54: 707-712.
- Le Duff, F.; Fontas, E.; Giaccherio, D.; Sillard, L.; Lacour, J.P.; Ortonne, J.P. et al. (2010):** 308-nm excimer lamp vs. 308-nm

- excimer laser for treating vitiligo: a randomized study. *Br. J. Dermatol.*, 163(1): 188-192.
- Lebwohl, M. and Ali, S. (2001):** Treatment of psoriasis. Part1. topical therapy and phototherapy. *J. Am. Acad. Dermatol.*, 45(4): 487-98, 499-502.
- Lebwohl, M.; Quijije, J.; Gilliard, J.; Rollin, T. and Watts, O. (2003):** Topical calcitriol is degraded by ultraviolet light. *J. Invest. Dermatol.*, 121(3): 594-595.
- Lee, K.J.; Choi, Y.L.; Kim, J.A.; Kim, M.G.; Lee, J.H.; Yang, J.M.; et al. (2007a):** Combination therapy of epidermal graft and systemic corticosteroid for vitiligo. *Dermatol. Surg.*, 33: 1002–1003.
- Lee, Y.; Seo, Y.J.; Lee, J.H. and Park, J.K. (2007b):** High-dose prednisolone and psoralen ultraviolet a combination therapy in 36 patients with vitiligo. *Clin. Exp. Dermatol.*, 32(5): 499-501.
- Lei, T.C.; Vieira, W.D. and Hearing, V.J. (2002):** In vitro migration of melanoblasts requires matrix metalloproteinase-2: implications to vitiligo therapy by photochemotherapy. *Pigment Cell Res.*, 15: 426–432.
- Leone, G.; Iacovelli, P.; Paro Vidolin, A. and Picardo, M. (2003):** Monochromatic excimer light 308 nm in the treatment of vitiligo: a pilot study. *J. Eur. Acad. Dermatol. Venereol.*, 17(5): 531-537.
- Leone, G.; Pacifico, A.; Iacovelli, P.; Paro Vidolin, A. and Picardo, M. (2006):** Tacalcitol and narrow-band phototherapy in patients with vitiligo. *Clin. Exp. Dermatol.*, 31: 200–205.
- Lepe, V.; Moncada, B.; Castanedo-Cazares, J.P.; Torres-Alvarez, M.B.; Ortiz, C.A. and Torres-Rubalcava, A.B. (2003):** A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. *Arch. Dermatol.*, 139(5): 581-585.
- Lin, S.J.; Jee, S.H.; Hsaio, W.C.; Lee, S.J. and Young, T.H. (2005):** Formation of melanocyte spheroids on the chitosan-coated surface. *Biomaterials*, 26: 1413–1422.
- Liu, J.B.; Li, M.; Chen, H.; Zhong, S.Q.; Yang, S.; Du, W.D.; et al. (2007):** Association of vitiligo with HLA-A2: a meta-analysis. *J. Eur. Acad. Dermatol. Venereol.*, 21: 205-213.
- Liu, J.Y.; Hafner, J.; Dragieva, G. and Burg, G. (2004):** Bioreactor microcarrier cell culture system (Bio-MCCS) for large-scale production of autologous melanocytes. *Cell Transplant.*, 13: 809–816.

- Liu, P.Y.; Bondesson, L.; Löntz, W. and Johansson, O. (1996):** The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study. *Arch. Dermatol. Res.*, 288(11): 670-675.
- Lo, K.K. (2006):** Proper use of topical corticosteroids and topical immunosuppressive agents. *Med. Bulletin*, 11(9): 4-5.
- Lontz, W.; Olsson, M.J.; Moellmann, G.; and Lerner, A.B. (1994):** Pigment cell transplantation for treatment of vitiligo: a progress report. *J. Am. Acad. Dermatol.*, 30: 591–597.
- Lotti, T.; Buggiani, G.; Troiano, M.; Assad, G.B.; Delescluse, J.; De Giorgi, V. et al. (2008):** Targeted and combination treatments for vitiligo. Comparative evaluation of different current modalities in 458 subjects. *Dermatol Ther*, 21 (Suppl. 1): S20–S26.
- Lotti, T.; Prignano, F. and Buggiani, G. (2007):** New and experimental treatments of vitiligo and other hypomelanoses. *Dermatol Clin*, 25: 393-400.
- Luger, T. and Paul, C. (2007):** Potential new indications of topical calcineurin inhibitors. *Dermatol*, 215 (Suppl. 1): S45–S54.
- Lu-yan, T.; Wen-wen, F.; Lei-hong, X.; Yi, J. and Zhi-zhong, Z. (2006):** Topical tacalcitol and 308-nm monochromatic excimer light: a synergistic combination for the treatment of vitiligo. *Photoderm. Photoimmunol. Photomed.*, 22: 310-314.
- Mahmoud, B.H.; Hexsel, C.L. and Hamzavi, I.H. (2008):** An update on new and emerging options for the treatment of vitiligo. *Skin. Therapy Lett.*, 13: 1–6.
- Majid, I. (2010):** Topical placental extract: Does it increase the efficacy of Narrowband UVB therapy in vitiligo. *Indian J. Dermatol. Venereol. Leprol.*, 76:254-258.
- Majid, I.; Masood, Q.; Hassan, I.; Khan, D. and Chisti M. (2009):** Childhood vitiligo : Response to methylprednisolone oral minipulse therapy and topical fluticasone combination. *Indian J. Dermatol.*, 54: 124-127.
- Malakar, S. and Lahiri, K. (2004):** Punch grafting for lip leucoderma. *Dermatol.*, 208: 125–128.
- Man, I.; Crombie, I.K. and Dawe, R.S. (2005):** The photocarcinogenic risk of narrowband TL-01 ultraviolet B therapy: early follow up data. *Br. J. Dermatol.*, 152: 755–757.

- Man, I.; Dawe R.S.; Ferguson, J. and Ibbotson, S.H. (2003):** An intraindividual study of the characteristics of erythema induced by bath and oral methoxsalen photochemotherapy and narrowband ultraviolet B. *Photochem. Photobiol.*, 78: 55-60.
- Mandelcorn-Monson, R.L.; Shear, N.H.; Yau, E.; Sambhara, S.; Barber, B.H.; Spaner, D.; et al. (2003):** Cytotoxic T lymphocyte reactivity to gp100, melan A/MART 1, and tyrosinase, in HLA-A2-positive vitiligo patients. *J. Invest. Dermatol.*, 121: 550-556.
- Mantovani, S.; Garbelli, S.; Palermo, B.; Campanelli, R.; Brazzelli, V.; Borroni, G.; et al. (2003):** Molecular and Functional Bases of Self-Antigen Recognition in Long-Term Persistent Melanocyte-Specific CD8⁺ T Cells in One Vitiligo Patient. *J. Invest. Dermatol.*, 121: 308-314.
- Masoudi, F.A.; Rathore, S.S.; Wang, Y.; Havranek, E.P.; Curtis, J.P.; Foody, J.M.; et al. (2004):** National patterns of use and effectiveness of angiotensin-converting enzyme inhibitors in older patients with heart failure and left ventricular systolic dysfunction. *Circulation*, 110: 724–731.
- Masuria, B.L.; Batra, A.; Kothiwala, R.K.; Khuller, R. and Sing, B. (1999):** Topical mometasone furoate for the treatment of childhood vitiligo. *Indian J. Dermatol. Venereol. Leprol.*, 65: 219-221.
- Mattoo, S.K.; Handa, S.; Kaur, I.; Gupta, N. and Malhotra, R. (2002):** Psychiatric morbidity in vitiligo: prevalence and correlates in India. *J. Eur. Acad. Dermatol. Venereol.*, 16(6): 573-578.
- McGovern, T.W.; Bologna, J. and Leffell, D.J. (1999):** Flip-top pigment transplantation: a novel transplantation procedure for the treatment of depigmentation. *Arch. Dermatol.*, 135: 1305–1307.
- McGregor, I.A. and McGregor, A.D. (1995):** Free skin grafts. *Fundamental techniques of plastic surgery*, 9th ed. Edinburgh: Churchill Livingstone, 35–39.
- Mehrabi, D. and Pandya, A.G. (2006):** A randomized, placebo-controlled, double-blind trial comparing narrowband UV-B Plus 0.1% tacrolimus ointment with narrowband UV-B plus placebo in the treatment of generalized vitiligo. *Arch. Dermatol.*, 142: 927–929.
- Menchini, G.; Tsourelis-Nikita, E. and Hercogova, J. (2003):** Narrow-band UV-B micro-phototherapy: a new treatment for vitiligo. *J. Eur. Acad. Dermatol. Venereol.*, 17: 171–177.

- Middelkamp-Hup, M.A.; Bos, J.D.; Rius-Diaz, F.; Gonzalez, S.; and Westerhof, W. (2007):** Treatment of vitiligo vulgaris with narrowband UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo controlled study. *J. Eur. Acad. Dermatol. Venereol.*, 21: 942–950.
- Millington, G.W. and Levell, N.J. (2007):** Vitiligo. The historical curse of depigmentation. *Int. J. Dermatol.*, 46(9): 990-995.
- Misri, R.; Khopkar, U.; Shankarkumar, U. and Ghosh, K. (2009):** Comparative case control study of clinical features and human leukocyte antigen susceptibility between familial and nonfamilial vitiligo. *Indian J. Dermatol. Venereol. Leprol.*, 75: 583-587.
- Mohammad, N.S.; Elgoweini, M.F. and Khadr, N.A. (2008):** Dermatomal Vitiligo: Therapeutic Implication of Dermabrasion. *J Pan-Arab League Dermatol.*, 19(1) : 21-29.
- Moretti, S. (2003):** Vitiligo. Orphanet Encyclopedia, accessed 20 October 2003, <<http://www.orpha.net/data/patho/GB/uk-vitiligo.pdf> 1>.
- Moretti, S. ; Spallanzani, A.; Amato, L.; Hautmann, G.; Gallerani, I.; Fabiani, M.; et al. (2002):** New insights into the pathogenesis of vitiligo: imbalance of epidermal cytokines at sites of lesions. *Pigment Cell Res.*, 15: 87-92.
- Mulekar, S.V. (2003):** Melanocyte-keratinocyte cell transplantation for stable vitiligo. *Int. J. Dermatol.*, 42: 132–136.
- Mulekar, S.V. (2004):** Long-term follow-up study of segmental and focal vitiligo treated by autologous non cultured melanocytes-keratinocyte cell transplantation. *Arch. Dermatol.*, 40: 1211-1215.
- Mulekar, S.V. (2005):** Long-term follow-up study of 142 patients with vitiligo vulgaris treated by autologous, non-cultured melanocyte-keratinocyte cell transplantation. *Int. J. Dermatol.*, 44: 841–845.
- Mulekar, S.V. (2006):** Stable vitiligo treated by a combination of low-dose oral pulse betamethasone and autologous, noncultured melanocyte-keratinocyte cell transplantation. *Dermatol. Surg.*, 32: 536–541.
- Mulekar, S.V. (2010):** Surgical management of vitiligo. *Expert. Rev Dermatol.*, 5(2): 229–239.
- Mulekar, S.V.; Al Eissa, A. and Asaad, M. (2005a):** Koebnerization of donor site in unilateral vitiligo patients, treated successfully by autologous, noncultured melanocyte-keratinocyte (MK) cell transplantation. *Clin. Exp. Dermatol.*, 30: 445–446.

- Mulekar, S.V.; Al Issa, A. and Al Eisa, A. (2009):** Treatment of vitiligo on difficult-to-treat sites using autologous noncultured cellular grafting. *Dermatol. Surg.*, 35: 66–71.
- Mulekar, S.V.; Al Issa, A.; Al Eisa, A. and Asaad, M. (2005b):** Genital vitiligo treated by autologous, noncultured melanocyte-keratinocyte cell transplantation. *Dermatol. Surg.*, 31: 1737–17340.
- Mulekar, S.V.; Asaad, M.; Ghwish, B.; Al Issa, A.; and Al Eisa, A. (2007):** Koebner phenomenon in vitiligo: not always an indication of surgical failure. *Arch. Dermatol.*, 143: 801–802.
- Mulekar, S.V.; Ghwish, B.; Al Issa, A.; and Al Eisa, A. (2008):** Treatment of vitiligo lesions by ReCell vs. conventional melanocyte-keratinocyte transplantation: a pilot study. *Br. J. Dermatol.*, 158: 45–49.
- Mutalik, S. (2007):** 'Surgical management of acral vitiligo'. In: Gupta S, Olsson MJ, Kanwar AJ, Ortonne JP, (eds.). *Surgical Management of Vitiligo*. Blackwell Publishing Ltd, 225–228.
- Mutalik, S. and Ginzburg, A (2000):** Surgical management of stable vitiligo: a review with personal experience. *Dermatol. Surg.*, 26: 248–254.
- Mysore, V. and Salim, T. (2009):** Cellular grafts in management of leucoderma. *Indian J. Dermatol.*, 54 (2): 142–149.
- Namazi, M.R. (2005):** Phenytoin as a novel anti-vitiligo weapon. *J. Autoimmun. Dis.*, 2: 11-15.
- Nanda, S.; Relhan, V.; Grover, C. and Reddy, B.S. (2006):** Suction blister epidermal grafting for management of eyelid vitiligo: special considerations. *Dermatol. Surg.*, 32: 387–391.
- Nath, S.K.; Majumder, P.P. and Nordlund, J.J. (1994):** Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. *Am. J. Hum. Genet.*, 55: 981–90
- Navarro-Zorraquino, M.; Garcia-Alvarez, F.; Martinez-Fernandez, A.R.; Pastor, C.; Larrad, L.; Salinas, J.C.; et al. (2007):** Pharmacological immunomodulation of surgical trauma. *J. Invest. Surg.*, 20: 283–289.
- Nicolaidou, E.; Antoniou, C.; Stratigos, A.J.; Stefanaki, C. and Katsambas, A.D. (2007):** Efficacy, predictors of response, and longterm follow-up in patients with vitiligo treated with narrowband UVB phototherapy. *J. Am. Acad. Dermatol.*, 56: 274–278.

- Njoo, M.D. and Westerhof, W. (2001):** Vitiligo: Pathogenesis and Treatment. *Am. J. Clinl. Dermatol.*, 2(3): 167-181.
- Njoo, M.D.; Bos, J.D. and Westerhof, W. (2000):** Treatment of generalized vitiligo in children with narrow- band UVB (TL-01) radiation therapy. *J. Am. Acad. Dermatol.*, 42: 245-253.
- Njoo, M.D.; Spuls, P.I.; Bos, J.D.; Westerhof, W. and Bossuyt, P.M.M. (1998):** Nonsurgical repigmentation therapies in vitiligo. Meta-analysis of the literature. *Arch. Dermatol.*, 134(12): 1532–1540.
- Njoo, M.D.; Vodegel, R.M. and Westerhof, W. (2000):** Depigmentation therapy in vitiligo universalis with topical 4-methoxyphenol and the Q-switched ruby laser. *J. Am. Acad. Dermatol.*, 42: 760– 769.
- Njoo, M.D.; Westerhof W.; Bos, J.D. and Bossuyt, P.M.M. (1999):** The Development of Guidelines for the Treatment of Vitiligo. *Arch. Dermatol.*, 135: 1514-1521.
- Nordlund, J.J. (2000):** Depigmentation for the treatment of extensive vitiligo. In: Hann SK, Nordlund JJ, (eds.). *Vitiligo*. France: Blackwell Science, 207–213.
- Ogg, G.S.; Rod Dunbar, P.; Romero, P.; Chen, J.L. and Cerundolo, V. (1998):** High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. *J. Exp. Med.*, 188: 1203–1208.
- Oh, C.K.; Cha, J.H.; Lim, J.Y.; Jo, J.H.; Kim, S.J.; Jang, H.S.; et al. (2001):** Treatment of vitiligo with suction epidermal grafting by the use of an ultrapulse CO2 laser with a computerized pattern generator. *Dermatol. Surg.*, 27: 565–568.
- Olsson, M.J. and Juhlin, L. (1998):** Leucoderma treated by transplantation of a basal cell layer enriched suspension. *Br. J. Dermatol.*, 138: 644–648.
- Ongenaes, K.; Beelaert, L.; Van Geel, N. and Naeyaert, J.M. (2006):** Psychosocial effects of vitiligo. *J. Eur. Acad. Dermatol. Venereol.*, 20(1) :1-8.
- Ongenaes, K.; Van Geel, N. and Naeyaert, J.M. (2003):** Evidence for an autoimmune pathogenesis of vitiligo. *Pigment Cell Res*, 16: 90-100.
- Osheroff, J.A. and Forsythe, D.E. (1991):** Buchanan BG. Bankowitz RA. Blumenfeld BH. Miller RA. Physicians' information needs: analysis of questions posed during clinical teaching. *Ann. Intl. Med.*, 114(7): 576-581.
-

- Ostovari, N.; Passeron, T.; Lacour, J.P. and Ortonne, J.P. (2006):** Lack of efficacy of tacrolimus in the treatment of vitiligo in the absence of UV-B exposure. *Arch. Dermatol.*, 142: 252–253.
- Oxman, A.D.; Sackett, D.L. and Guyatt, G.H. (1993):** Users' guides to the medical literature. I. How to get started. *J. Am. Med. Ass.*, 270: 2093–2095.
- Özdemir, M.; Cetinkale, O.; Wolf, R.; Kotoπryan, A.; Mat, C.; Tüzün, B.; et al. (2002):** Comparison of two surgical approaches for treating vitiligo: a preliminary study. *Int. J. Dermatol.*, 41:135–138.
- Pai, G.S.; Vinod, V.; and Joshi, A. (2002):** Efficacy of erbium YAG laser-assisted autologous epidermal grafting in vitiligo. *J. Eur. Acad. Dermatol. Venereol.*, 16(6): 604-606.
- Pal, P.; Mallick, S.; Mandal, S.K.; Das, M.; Dutta, A.K.; Datta, P.K.; et al. (2002):** A human placental extract: In vivo and in vitro assessment of its melanocytes growth and pigment-inducing activities. *Int. J. Dermatol.*, 41: 760-761.
- Pal, P.; Roy, R.; Datta, P.K.; Dutta, A.K.; Biswas, B. and Bhadra, R. (1995):** Hydroalcoholic human placental extract: Skin pigmenting activity and gross chemical composition. *Int. J. Dermatol.*, 34: 61-66.
- Palermo, B.; Campanelli, R.; Garbelli, S.; Mantovani, S.; Lantelme, E.; Brazzelli, V. et al. (2001):** Specific cytotoxic T lymphocyte responses against MelanA/MART1, tyrosinase and Gp100 in vitiligo by the use of major histocompatibility complex/peptide tetramers: the role of cellular immunity in the etiopathogenesis of vitiligo. *J. Invest. Dermatol.*, 117: 326–332.
- Pandya, V.; Parmar, K.S.; Shah, B.J. and Bilimoria, F.E. (2005):** A study of autologous melanocyte transfer in treatment of stable vitiligo. *Indian J. Dermatol. Venereol. Leprol.*, 71: 393–397.
- Panuncio, A.L. and Vignale, R. (2003):** Ultrastructural studies in stable vitiligo. *Am. J. Dermatopathol.*, 25(1): 16-20
- Papadopoulos, L.; Bor, R. and Legg, C. (1999):** Psychological factors in cutaneous disease, an overview of research. *Psychol. Health Med.*, 4: 107– 126.
- Park, H.S.; Lee, Y.S. and Chun, D.K. (2003):** Squamous cell carcinoma in vitiligo lesion after long-term PUVA therapy. *J. Eur. Acad. Dermatol. Venereol.*, 17: 578-580.

- Parsad, D. and Gupta, S. (2008):** Standard guidelines of care for vitiligo surgery. *Indian J. Dermatol. Venereol. Leprol.*, 74 (Suppl. 1): 37– 45.
- Parsad, D.; Bhatnagar, A. and De, D. (2010):** Narrowband ultraviolet B for the treatment of vitiligo. *Expert. Rev. Dermatol.*, 5(4): 445–459.
- Parsad, D.; Kanwar, A.J. and Kumar, B. (2006):** Psoralen-ultraviolet A vs. narrow-band ultraviolet B phototherapy for the treatment of vitiligo. *J Eur Acad Dermatol Venereol*, 20(2): 175–177.
- Parsad, D.; Pandhi, R. and Juneja, A. (2003):** Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. *Clin. Exp. Dermatol.*, 28: 285–287.
- Parsad, D.; Saini, R. and Verma, N. (1998):** Combination of PUVASOL and topical calcipotriol in vitiligo. *Dermatol.*, 197: 167–170.
- Pasricha, J. S. and Khaitan, B.K. (2007):** oral mini-pulse therapy with betamethasone in vitiligo patients having extensive or fast-spreading disease. *Int. J. Dermatol.*, 32(10): 753-757.
- Passeron, T. and Ortonne, J.P. (2006):** Use of the 308-nm excimer laser for psoriasis and vitiligo. *Clin. Dermatol.*, 24: 33–42.
- Passeron, T.; Ostovari, N.; Zakaria, W.; Fontas, E.; Larrouy, J.C.; Lacour J.P.; et al. (2004):** Topical tacrolimus and the 308nm excimer laser: a synergistic combination for the treatment of vitiligo. *Arch. Dermatol.*, 140(9): 1065-1069.
- Pehlivan, S.; Ozkinay, F.; Alper, S.; Onay, H.; Yuksel, E.; Pehlivan, M.; et al. (2009):** Association between IL4 (–590), ACE (I)/(D), CCR5 (Δ 32), CTLA4 (+49) and IL1-RN (VNTR in intron 2) gene polymorphisms and vitiligo. *Eur. J. Dermatol.*, 19(2): 126-128.
- Perry-Parrish, C. and Dodge, R. (2010):** Research and statistics: validity hierarchy for study design and study type. *Pediatr. Rev.*, 31(1): 27- 29.
- Phillips, B.; Ball, C. and Sackett, D. (2007):** Levels of evidence and grades of recommendation, accessed 2 April 2007, <[http://www.cebm.net/ levels of evidence.asp](http://www.cebm.net/levels_of_evidence.asp)>.
- Phillips, J.; Gawkrödger, D.J.; Caddy, C.M.; Hedley, S.; Dawson, R.A.; Smith-Thomas, L.; et al. (2001):** Keratinocytes suppress TRP-1 expression and reduce cell number of co-cultured melanocytes – implications for grafting of patients with vitiligo. *Pigment Cell Res.*, 14: 116–125.

- Pianigiani, E.; Risulo, M.; Andreassi, A.; Taddeucci, P.; Ierardi, F. and Andreassi, L. (2005):** Autologous epidermal cultures and narrow-band ultraviolet B in the surgical treatment of vitiligo. *Dermatol. Surg.*, 31: 155–159.
- Radakovic, S.; Breier-Maly, J.; Konschitzky, R. and Kittler, H. (2009):** Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective.; randomized.; observer- blinded trial. *J. Eur. Acad. Dermatol. Venereol.*, 23(8): 951– 953.
- Radmanesh, M. (2000):** Depigmentation of the normally pigmented patches in universal vitiligo patients by cryotherapy. *J. Eur. Acad. Dermatol. Venereol.*, 14: 149–152.
- Radmanesh, M. and Saedi, K. (2006):** The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. *J. Dermatolog. Treat.*, 17: 151–153.
- Rai, R. and Srinivas, C.R. (2007):** Photoprotection. *Indian J. Dermatol. Venereol. Leprol.*, 73: 73-79.
- Rao, J. and Fitzpatrick, R.E. (2004):** Use of the Q-switched 755-nm alexandrite laser to treat recalcitrant pigment after depigmentation therapy for vitiligo. *Dermatol. Surg.*, 30: 1043–1045.
- Rao, S.J. (2003):** Regression Modeling Strategies with Applications to Linear Models, Logistic Regression, and Survival Analysis. *J. Am. Statis. Ass.*, 98 (461): 257-258.
- Rastogi, S.; Goyal, P.; Mangla, K.; Bhavsar, N.; Patel, H. and Rawal R.C. (2006):** Study of transplantation of melanocyte keratinocyte suspension in treatment of vitiligo. *Indian J. Dermatol.*, 51: 142–144
- Rateb, A.A.H.; Azzam, O.A.; Rashed, L.A.; EL-Guindy, N.M. and Salah El-Din, M. (2004):** The role of nerve growth factor in the pathogenesis of vitiligo. *J. Egypt. Wom. Dermatol. Soc.*,1(1):18-24.
- Rath, N.; Kar, H.K. and Sabhnani, S. (2008):** An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad / narrow band UVB phototherapy in progressive vitiligo. *Indian J. Dermatol. Venereol. Leprol.*, 74(4): 357-360.
- Rätsep, R.; Kingo, K.; Karelson, M.1, Reimann, E., Raud, K., Silm, H.; et al. (2008):** Gene expression study of IL10 family genes in vitiligo skin biopsies, peripheral blood mononuclear cells and sera. *Br. J. Dermatol.*, 159(6): 1275-1281.

- Redondo, P.; Del Olmo, J.; Garcva-Guzman, M.; Guembe, L. and Prósper F. (2008):** Repigmentation of vitiligo by transplantation of autologous melanocyte cells cultured on amniotic membrane. *Br. J. Dermatol.*, 158: 1168–1171.
- Rezaei, N., Gavalas N.G., Weetman, A.P. and Kemp, E.H. (2007):** Autoimmunity as an aetiological factor in vitiligo. *J. Eur. Acad. Dermatol. Venereol.*, 21 (7): 865-876.
- Rittie, L. and Fisher, G.J. (2002):** UV-light-induced signal cascades and skin aging. *Ageing. Res. Rev.*, 1: 705-720.
- Rocha, I.M.; Oliveira, L.J.; De Castro, L.C.; De Araújo Pereira, L.I.; Chaul, A.; Guerra, J.G.; et al. (2002):** Recognition of melanoma cell antigens with antibodies present from patients with vitiligo. *Int. J. Dermatol.*, 39: 840–843.
- Rodríguez-Martín, M.; García Bustínduy, M.; Sáez Rodríguez, M. and Noda Cabrera, A. (2009):** Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. *Br. J. Dermatol.*, 160(2): 409-414.
- Roelandts, R. (2003):** Photo(chemo) therapy for vitiligo. *Photodermatol. Photoimmunol. Photomed.*, 19(1): 1-4.
- Rubin, D.B. (1997):** Estimating causal effects from large data sets using propensity scores. *Ann. Intern. Med.*, 127: 757–763.
- Sachdev, M. and Shankar, D.S. (2000).** Dermatologic surgery: pulsed erbium: YAG laser-assisted autologous epidermal punch grafting in vitiligo. *Int. J. Dermatol.*, 39: 868–871.
- Sackett, D.L.; Haynes, R.B.; Guyatt, G.H. and Tugwell, P. (1991):** *Clinical Epidemiology: A Basic Science for Clinical Medicine.* Boston: Little, Brown and Co., 400: 441.
- Sackett, D.L.; Rosenberg, W.M.; Gray, J.A.; Haynes, R.B. and Richardson, W.S. (1996):** Evidence based medicine: what it is and what it isn't. *Br. Med. J.*, 312: 71-72.
- Sackett, D.L.; Straus, S.E.; Richardson, W.S.; Rosenberg, W. and Haynes, R.B (2000):** Evidence-based medicine: how to practice and teach EBM, 2nd ed. Edinburgh & New York: Churchill Livingstone, 29-37.

- Sanclemente, G.; Garcia, J.J.; Zuleta, J.J.; Diehl, C.; Correa, C. and Falabella, R. (2008):** A double-blind, randomized trial of 0.05% betamethasone vs. topical catalase/dismutase superoxide in vitiligo. *J. Eur. Acad. Dermatol. Venereol.*, 22(11): 1359-1364.
- Saraceno, R.; Nisticò, S.P.; Capriotti, E. and Chimenti, S. (2009):** Monochromatic excimer light 308 nm in monotherapy and combined with topical khellin 4% in the treatment of vitiligo: a controlled study. *Dermatol. Ther.*, 22(4): 391-394.
- Saraswat, A. (2010):** Topical corticosteroid use in children: Adverse effects and how to minimize them. *Indian J. Dermatol. Venereol. Leprol.*, 76: 225-228.
- Sardana, K.; Bhushan, P.; and Kumar, Garg, V. (2007):** Effect of tacrolimus on vitiligo in absence of UV radiation exposure. *Arch. Dermatol.*, 143(1): 119-122.
- Sardi, J.R. (2001):** Surgical treatment for vitiligo through hair follicle grafting: how to make it easy. *Dermatol. Surg.*, 27(7): 685–686.
- Sassi, F.; Cazzaniga S.; Tessari, G.; Chatenoud, L.; Reseghetti, A.; Marchesi, L.; et al. (2008):** Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. *Br. J. Dermatol.*, 159(5): 1186–1191.
- Schallreuter, K.U.; Bahadoran, P.; Picardo, M.; Panske, A. and Wood, J.M. (2008b):** Vitiligo pathogenesis: autoimmune disease, genetic defect, excessive reactive oxygen species, calcium imbalance, or what else? *Exp. Dermatol.*, 17: 139-140.
- Schallreuter, K.U.; Moore, J.; Behrens-Williams, S.; Panske, A. and Harari, M. (2002):** Rapid initiation of re-pigmentation in vitiligo with dead sea climatotherapy in combination with pseudo catalase (PC-KUS). *Int. J. Dermatol.*, 41:482-487.
- Schallreuter, K.U.; Moore, J.; Wood, J.M.; Beazley, W.D.; Gaze, D.C.; Tobin, D.J.; et al. (1999):** In vivo and in vitro evidence for hydrogen peroxide (H₂O₂) accumulation in the epidermis of patients with vitiligo and its successful removal by a UVB-activated pseudocatalase. *J. Investig. Dermatol. Symp. Proc.*, 4(1): 91-96.
- Schallreuter, K.U.; Moore, J.; Wood, J.M.; Beazley, W.D.; Peters, E.M.; Marles, L.K.; et al. (2001):** Epidermal H₂O₂ accumulation alters tetrahydrobiopterin (6BH4) recycling in vitiligo: identification

of a general mechanism in regulation of all 6BH4-dependent processes? *J. Invest. Dermatol.*, 116: 167–174.

Schallreuter, K.U.; Rübsam, K.; Gibbons, N.C.; Maitland, D.J.; Chavan, B.; Zothner, C.; et al. (2008a): Methionine sulfoxide reductases A and B are deactivated by hydrogen peroxide (H₂O₂) in the epidermis of patients with vitiligo. *J. Invest. Dermatol.*, 128(4): 808-815.

Schallreuter, K.U.; Wood, J.M.; Lemke, K.R. and Levenig, C. (1995): Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. *Dermatol.*, 190: 223–229.

Schardt, C.; Adams, M.B.; Owens, T.; Keitz, S. and Fontelo, P. (2007): Utilization of the PICO framework to improve searching PubMed for clinical questions. *B.M.C. Med. Inform. Decis. Mak.*, 7: 16-20.

Sehgal, V.N and Srivastava, G. (2007): Vitiligo: Compendium of clinico-epidemiological features. *Indian. J. Dermatol. Venereol. Leprol.*, 73: 149-156.

Sehgal, V.N. (2004): Vitiligo. *Textbook of clinical Dermatology*. 4th (ed.). Jaypee: New Delhi, 99-101.

Sehgal, V.N.; Srivastava, G. and Dogra, S. (2008): Tacrolimus in dermatology-pharmacokinetics.; mechanism of action.; drug interactions.; dosages.; and side effects: part I, 27–30.

Seiraf, H.; Farnaghi, F.; Firooz, A. and Vasheghani-Farahani, A. (2007): Pimecrolimus cream in repigmentation of vitiligo. *Dermatol.*, 214: 253–259.

Selvaraj, S.; t Kumar, Y.; Elakiya, M.; Saraswathi, P.C.; Balaji, D.; Nagamani, P.; et al. (2010): Evidence-based medicine - a new approach to teach medicine: a basic review for beginners. *Biol. Med.*, 2 (1): 1-5.

Sendur, N.; Karaman, G.; Sanic, N. and Savk, E. (2006): Topical pimecrolimus: a new horizon for vitiligo treatment? *J. Dermatol. Treat.*, 17: 338–342.

Sethi, S.; Mahajan, B.B.; Gupta, R.R. and Ohri, A. (2007): Comparative evaluation of the therapeutic efficacy of dermabrasion, dermabrasion combined with topical 5% 5-fluorouracil cream, and dermabrasion combined with topical placentrex gel in localized stable vitiligo. *Int. J. Dermatol.*, 46: 875-879.

- Shajil, E.M.; Chatterjee, S.; Agrawal, D.; Bagchi, T. and Begum, R. (2006):** Vitiligo: Pathomechanisms and genetic polymorphism of susceptibility genes, *Indian J. Exp. Biol.*, 44:526-539.
- Shaneyfelt, T., Baum, K.D.; Bell, D.; Feldstein, D.; Houston, T.K.; Kaatz, S.; et al. (2006):** Instruments for Evaluating Education in Evidence-Based Practice: A Systematic Review. *J. Am. Med. Ass.*, 296(9): 1116-1127.
- Shwartz, R.A. and Janniger, C.K. (1997):** Vitiligo. *Cutis*, 60: 239-244.
- Silva, M. (2004):** The psychological aspects of vitiligo. *Cutis*, 73: 163-167.
- Silverberg, N.B. and Nanette, B. (2010):** Update on childhood vitiligo. *Curr. Opin. Pediatr.*, 22(4): 445–452.
- Silverberg, N.B.; Lin, P.; Travis, L.; Farley-Li, J.; et al. (2004):** Tacrolimus ointment promotes repigmentation of vitiligo in children: a review of 57 cases. *J. Am. Acad. Dermatol.*, 51(5):760–766.
- Singh, A.K. and KarKi, D. (2010):** Micropigmentation: tattooing for the treatment of lip vitiligo. *J. Plast. Reconstr. Aesthet. Surg.*, 63(6): 988-991.
- Sinha, M. (2005):** Meshing small skin grafts manually: A simple, quick and effective method using discard-a-pad. *Ann. Plast. Surg.*, 55: 433–434.
- Sitek, J.C.; Loeb, M. and Ronnevig, J.R. (2007):** Narrowband UVB therapy for vitiligo: does the repigmentation last? *J. Eur. Acad. Dermatol. Venereol.*, 21 (7): 891-896.
- Skaehill, P.A. (2001):** Tacrolimus in dermatologic disorder. *Ann. Pharmacother.*, 35(5): 582–588.
- Smith, R. (1996):** What clinical information do doctors need? *Br. Med. J.*, 313: 1062-1068.
- Spencer, J.D.; Gibbons, N.C.; Rokos, H.; Peters, E.M.; Wood, J.M. and Schallreuter, K.U. (2007):** Oxidative stress via hydrogen peroxide affects proopiomelanocortin peptides directly in the epidermis of patients with vitiligo. *J. Investig. Dermatol.*, 127: 411-420.
- Spencer, J.M. and Hadi, S.M. (2004):** The excimer lasers. *J. Drugs. Dermatol.*, 3: 522-525.
- Spencer, J.M.; Nossa, R. and Ajmeri, J. (2002):** Treatment of vitiligo with the 308-nm excimer laser: a pilot study. *J. Am. Acad. Dermatol.*, 46: 727-731.

- Spritz, R.A. (2008):** The genetics of generalized vitiligo. *Curr. Dir. Autoimmun.*,10:244-57.
- Sravani, P.V.; Babu, N.K.; Gopal, K.; Rama Rao, G.R.; Rao, A.R.; Moorthy, B.; et al. (2009):** Determination of oxidative stress in vitiligo by measuring superoxide dismutase and catalase levels in vitiliginous and non-vitiliginous skin. *Indian J. Dermatol. Venereol. Leprol.*,75: 268-271
- Srinivas, C.R. and Rai, R. (2004):** Uday Kumar P. Meshed split skin graft for extesive vitiligo. *Indian J Dermatol Venereol Leprol*, 70: 165–167.
- Stern, R.S. and Laird, N. (1994):** The carcinogenic risk of treatments for severe psoriasis Photochemotherapy follow-up study. *Cancer*, 73: 2759-2764.
- Stern, R.S. and Lunder, E.J. (1998):** Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). A meta analysis. *Arch. Dermatol.*, 134: 1582-1585.
- Stinco, G.; Piccirillo, F.; Forcione, M.; Valent, F. and Patrone P. (2009):** An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. *Eur. J. Dermatol.*, 19(6): 588-593
- Sun, X.; Xu, A.; Wei, X.; Ouyang, J.; Lu, L.; Chen, M. and Zhang, D. (2006):** Genetic epidemiology of vitiligo: a study of 815 probands and their families from south China. *Int. J. Dermatol.*, 45(10): 1176–1181.
- Szell, M.; Baltas, E.; Bodai, L.; Zsuzsanna, B.C.; , Nikoletta, N. , Attila, D.; et al. (2008):** The Argl60Trp allele of Melanocortin-1 receptor gene might protect against vitiligo. *Photochem. Photobiol.*, 84: 565-571.
- Tag, A.; Westerhof, W.; Abdel-Rahman, A.; El-Khayyat, M. and El-Metwally, Y. (2006):** Treatment of periungual vitiligo with erbium-YAG-laser plus 5-flurouracil: a left to right comparative study. *J. Cosmet. Dermatol.*, 5: 135–139.
- Taieb, A. (2000):** Intrinsic and extrinsic pathomechanisms in vitiligo. *Pigment Cell Res.*, 13:41-47.
- Taieb, A. and Picardo, M. (2007):** The definition and assessment of vitiligo: a consensus report of the vitiligo European task force. *Pigment Cell Res.*, 20(1): 27-35.

- Tamesis, M.E.B. and Morelli, J.G. (2010):** Vitiligo treatment in childhood: A state of the art review. *Pediatr. Dermatol.*, 27(5): 437-445.
- Tanghetti, E.A. (2003):** Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. *Cutis*, 71(2): 158-62.
- Tegta, G.R.; Parsad, D.; Majumdar, S. and Kumar, B. (2006):** Efficacy of autologous transplantation of noncultured epidermal suspension in two different dilutions in the treatment of vitiligo. *Int. J. Dermatol.*, 45: 106–110.
- Thami, G.P. (2007):** 'Micropigmentation'. In: Gupta BS, Olsson MJ, Kanwar AJ and Ortonne JP, (eds.). *Surgical Management of Vitiligo*. Singapore: Blackwell Publishing, 249–254.
- The Framingham Study. (2007):** Accessed 13 December 2007, <<http://www.nhlbi.nih.gov/about/framingham/index.html>>.
- Thissen, M. and Westerhof, W. (1997):** Laser treatment for further depigmentation in vitiligo. *Int. J. Dermatol.*, 36 (5): 386-388.
- Thomson, A.R.; Kent, G. and Smith, J.A. (2002):** Living with vitiligo: dealing with difference. *Br. J. Health. Psychol.*, 7: 213–225.
- Timmermans, S. and Mauck, A. (2005):** The promises and pitfalls of evidence-based medicine. *Health Aff.*, 24 (1): 18–28.
- Tjioe, M.; Gerritsen, M.J.; Juhlin, L. and van de Kerkhof, P.C. (2002):** Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. *Acta. Dermatovenerol.*, 82: 369–372.
- Torpy, J.M.; Lynn, C. and Glass, R.M. (2009):** Evidence-Based Medicine. *J. Am. Med. Ass.*, 301(8): 900-915.
- Trapani, J.A. and Sutton, V.R. (2003):** Granzyme B: pro-apoptotic, antiviral and antitumor functions. *Curr. Opin. Immunol.*, 15: 533-543.
- Travis, L.B. and Silverberg, N.B. (2004):** Calcipotriene and corticosteroid combination therapy for vitiligo. *Pediatr. Dermatol.*, 21(4): 495-8.
- Tsukamoto, K.; Osada, A.; Kitamura, R.; Ohkouchi, M.; Shimada, S. and Takayama, O. (2002):** Approaches to repigmentation of vitiligo skin: new treatment with ultrasonic abrasion, seed-grafting and psoralen plus ultraviolet A therapy. *Pigment Cell Res.*, 15: 331–334.

- Tu, C.X.; Gu, J.S. and Lin, X.R. (2003):** Increased interleukin-6 and granulocyte-macrophage colony stimulating factor levels in the sera of patients with non-segmental vitiligo. *J. Dermatol. Sci.*, 31: 73-78.
- Turner, B.J. and Laine, C. (2001):** Differences between generalists and specialists: knowledge, realism, or primum non nocere? *J. Gen. Intern. Med.*, 16: 422-424.
- Valkova, S.; Trashlieva M. and Christova, P. (2004):** Treatment of vitiligo with local khellin and UVA: Comparison with systemic PUVA. *Clin. Exp. Dermatol.*, 29(2):180-184.
- Van den Wijngaard, R.; Wankowicz-Kalinska, A.; Le Poole, C.; Tigges, B.; Westerhof, W. and Das, p. (2000):** Local immune response in skin of generalized vitiligo patients. Destruction of melanocytes is associated with the prominent presence of CLA T cells at the perilesional site. *Lab. Investig.*, 80: 1299-1309.
- Van Geel, N., Ongenae, K.; Vander Haeghen, Vervae, C. and Naeyaert, J.M. (2006):** Subjective and objective evaluation of noncultured epidermal cellular grafting for repigmenting vitiligo. *Dermatol.*, 213(1): 23-29.
- Van Geel, N.; Ongenae, K.; De Mil, M. and Naeyaert, J.M. (2001):** Modified technique of autologous noncultured epidermal cell transplantation for repigmenting vitiligo: a pilot study. *Dermatol Surg*, 27: 873–876.
- Van Geel, N.; Ongenae, K.; De Mil, M.; Haeghen, Y.V.; Vervae C. and Naeyaert J.M. (2004):** Double-blind placebo-controlled study of autologous transplanted epidermal cell suspensions for repigmenting vitiligo. *Arch. Dermatol.*, 140: 1203–1208.
- Venneker, G.T.; Westerhof, W.; de Vries, I.J.; Drayer, N.M.; Wolthers, B.G.; de Waal, L.P.; et al. (1992):** Molecular heterogeneity of the fourth component of complement (C4) and its genes in vitiligo. *J. Invest. Dermatol.*, 853-858.
- Wankowicz-Kalinska, A.; Van den Wijngaard, R.M.; Tigges, B.J.; Westerhof, W.; Ogg, G.S.; Cerundolo, V.; et al. (2003):** Immunopolarization of CD4+ and CD8+ T cells to type-1-like is associated with melanocyte loss in human vitiligo. *Lab. Invest.*, 83(5): 683-695.
- Westerhof, W. and Nieuweboer-Krobotova, L. (1997):** Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. *Arch. Dermatol.*, 133: 1591– 1592.

- Westerhof, W.; Nieuweboer-Krobotova, L.; Mulder, P.G.H. and Glazenburg, E.J. (1999):** Left–right comparison study of the combination of fluticasone propionate and UV-A vs. either fluticasone propionate or UV-A alone for the long-term treatment of vitiligo. *Arch. Dermatol.*, 135: 1061–1066.
- Whitton, M.E.; Ashcroft, D.M.; Barrett, C. and González, U. (2006):** Interventions for vitiligo. *Cochrane Database Syst. Rev.*, 25(1): 32-36.
- Winiski, A.; Wang, S.; Schwendinger, B. and Stuetz, A. (2007):** Inhibition of T-cell activation in vitro in human peripheral blood mononuclear cells by pimecrolimus and glucocorticosteroids and combinations thereof. *Exp. Dermatol.*, 16: 699–704.
- Woolf, S.H. and George, J.N. (2000):** Evidence-based medicine. Interpreting studies and setting policy. *Hematol. Oncol. Clin. North. Am.*, 14 (4): 761–784.
- Wu, C.S.; Hu, S.C.; Lan, C.C.; Chen, G.S.; Chuo, W.H. and Yu, H.S. (2008):** Low-Energy Helium-Neon Laser Therapy Induces Repigmentation and Improves the Abnormalities of Cutaneous Microcirculation in Segmental-Type Vitiligo Lesions. *Kaohsiung J. Med. Sci.*, 24(4): 180-189.
- Xu, A.E.; Zhang, D.M.; Wei, X.D.; Hang, B.; et al. (2009):** Efficacy and safety of tacrolimus cream 0.1% in the treatment of vitiligo. *Int. J. Dermatol.*, 48(1):86–90.
- Yee, C.; Thompson, J.A.; Roche, P.; Byrd, D.R.; Lee, P.P.; Piepkorn, M.; et al. (2001):** Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. *J. Exp. Med.*, 192(11): 1637-1644.
- Yildirim, M.; Baysal, V.; Inaloz, H.S. and Can, M. (2004):** The role of oxidants and antioxidants in generalized vitiligo at the tissue level. *J. Eur. Acad. Dermatol. Venereol.*, 18:683-686.
- Yildirim, M.; Baysal, V.; Inaloz, H.S.; Kesici, D. and Delibas, N. (2003):** The role of oxidants and antioxidants in generalized vitiligo. *J. Dermatol.*, 30:104-108.
- Yones, S.S.; Palmer, R.A.; Garibaldinos, T.M. and Hawk, J.L. (2007):** Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen-UV-A therapy vs Narrowband-UV-B therapy. *Arch. Dermatol.*, 143: 578-584.

- Yu, H.S.; Chang, K.L.; Yu, C.L.; Li, H.F.; Wu, M.T.; Wu C.S.; et al. (1997):** Alterations in IL-6, IL-8, GM-CSF, TNF-alpha, and IFN-gamma release by peripheral mononuclear cells in patients with active vitiligo. *J. Invest. Dermatol.*, 108:527-529.
- Yu, H.S.; Kao, C.H. and Yu, C.L. (1993):** Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. *J. Invest. Dermatol.*, 100: 823–828.
- Yu, H.S.; Wu, C.S.; Yu, C.L.; Kao, Y.H. and Chiou, M.H. (2003) :** Helium-neon laser irradiation stimulates migration and proliferation in melanocytes and induces repigmentation in segmental-type vitiligo. *J. Invest. Dermatol.*, 120(1): 56-64.
- Yuksel, E.P.; Aydin, F.; Senturk, N.; Canturk, T. and Turanli, A.Y. (2009):** Comparison of the efficacy of narrow band ultraviolet B and narrow band ultraviolet B plus topical catalase-superoxide dismutase treatment in vitiligo patients. *Eur. J. Dermatol.*, 19 (4): 341-344.
- Zaki, M.S.E. and Elbatrawy, A.M. (2009):** Catecholamine Level and Its Relation to Anxiety and Depression in Patients with Vitiligo. *J. Egypt Women. Dermatol. Soc.*, 6(2): 74-79.
- Zanini, M. and Machado Filho, C.D.A.S. (2005):** Terapia despigmentante para vitiligo generalizado com solução tópica de fenol 88%. *Ann. Brasil. Dermatol.*, 80(4): 415-416.
- Zhang, X.J.; Chen, J.J. and Liu, J.B. (2005):** The genetic concept of vitiligo. *J. Dermatol. Sci.*, 39:137-46.
- Zhang, X.Y.; He, Y.L.; Dong, J.; Xu, J.Z. and Wang, J. (2010):** Clinical efficacy of a 308nm excimer laser in the treatment of vitiligo. *Photodermatol. Photoimmunol. Photomed.*, 26: 138-142.